前往化源商城

Tissue Engineering, Part A: Tissue Engineering 2015-02-01

Dual-phase osteogenic and vasculogenic engineered tissue for bone formation.

Rameshwar R Rao, Marina L Vigen, Alexis W Peterson, David J Caldwell, Andrew J Putnam, Jan P Stegemann

文献索引:Tissue Eng. Part A 21(3-4) , 530-40, (2015)

全文:HTML全文

摘要

Minimally invasive, injectable bone tissue engineering therapies offer the potential to facilitate orthopedic repair procedures, including in indications where enhanced bone regeneration is needed for complete healing. In this study, we developed a dual-phase tissue construct consisting of osteogenic (Osteo) and vasculogenic (Vasculo) components. A modular tissue engineering approach was used to create collagen/fibrin/hydroxyapatite (COL/FIB/HA) hydrogel microbeads containing embedded human bone marrow-derived mesenchymal stem cells (bmMSC). These microbeads were predifferentiated toward the osteogenic lineage in vitro for 14 days, and they were then embedded within a COL/FIB vasculogenic phase containing a coculture of undifferentiated bmMSC and human umbilical vein endothelial cells (HUVEC). In vitro studies demonstrated homogenous dispersion of microbeads within the outer phase, with endothelial network formation around the microbeads over 14 days in the coculture conditions. Subcutaneous injection into immunodeficient mice was used to investigate the ability of dual-phase (Osteo+Vasculo) and control (Osteo, Vasculo, Blank) constructs to form neovasculature and ectopic bone. Laser Doppler imaging demonstrated blood perfusion through all constructs at 1, 4, and 8 weeks postimplantation. Histological quantification of total vessel density showed no significant differences between the conditions. Microcomputed tomography indicated significantly higher ectopic bone volume (BV) in the Osteo condition at 4 weeks. At 8 weeks both the Osteo and Blank groups exhibited higher BV compared to the Vasculo and dual Osteo+Vasculo groups. These data not only show that osteogenic microbeads can be used to induce ectopic bone formation, but also suggest an inhibitory effect on BV when undifferentiated bmMSC and HUVEC were included in dual-phase constructs. This work may lead to improved methods for engineering vascularized bone tissue, and to injectable therapies for the treatment of orthopedic pathologies in which bone regeneration is delayed or prevented.

相关化合物

结构式 名称/CAS号 全部文献
八甲基三硅氧烷 结构式 八甲基三硅氧烷
CAS:107-51-7
氢氧化钠 结构式 氢氧化钠
CAS:1310-73-2
六甲基二硅氧烷 结构式 六甲基二硅氧烷
CAS:107-46-0
3-乙基-2,4-戊烷二酮 结构式 3-乙基-2,4-戊烷二酮
CAS:1540-34-7
冰醋酸 结构式 冰醋酸
CAS:64-19-7
DL-正亮氨酸 结构式 DL-正亮氨酸
CAS:616-06-8
曲拉通X-100 结构式 曲拉通X-100
CAS:9002-93-1
地塞米松 结构式 地塞米松
CAS:50-02-2
雄诺龙 结构式 雄诺龙
CAS:521-18-6
4',6-二脒基-2-苯基吲哚二盐酸盐 结构式 4',6-二脒基-2-苯基吲哚二盐酸盐
CAS:28718-90-3